IRIS Accounts Production v23.3.0.418 SC377195 director 6.4.22 5.4.23 5.4.23 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC3771952022-04-05SC3771952023-04-05SC3771952022-04-062023-04-05SC3771952021-04-05SC3771952021-04-062022-04-05SC3771952022-04-05SC377195ns14:PoundSterlingns10:Original2022-04-062023-04-05SC377195ns10:Originalns10:Director12022-04-062023-04-05SC377195ns10:Original2022-04-062023-04-05SC377195ns10:Original2023-04-05SC377195ns10:Originalns10:PrivateLimitedCompanyLtd2022-04-062023-04-05SC377195ns10:Originalns10:SmallEntities2022-04-062023-04-05SC377195ns10:Originalns10:AuditExempt-NoAccountantsReport2022-04-062023-04-05SC377195ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-04-062023-04-05SC377195ns10:SmallCompaniesRegimeForAccountsns10:Original2022-04-062023-04-05SC377195ns10:Originalns10:FullAccounts2022-04-062023-04-05SC377195ns10:Original12022-04-062023-04-05SC377195ns10:Original2022-04-05SC377195ns10:Originalns5:CurrentFinancialInstruments2023-04-05SC377195ns10:Originalns5:CurrentFinancialInstruments2022-04-05SC377195ns10:Originalns5:Non-currentFinancialInstruments2023-04-05SC377195ns10:Originalns5:Non-currentFinancialInstruments2022-04-05SC377195ns5:ShareCapitalns10:Original2023-04-05SC377195ns5:ShareCapitalns10:Original2022-04-05SC377195ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-04-05SC377195ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-04-05SC377195ns10:PrivateLimitedCompanyLtd2022-04-062023-04-05SC377195ns10:Originalns5:NetGoodwill2022-04-062023-04-05SC377195ns10:Originalns5:PlantMachinery2022-04-062023-04-05SC377195ns10:Original2021-04-062022-04-05SC377195ns10:Originalns5:NetGoodwill2022-04-05SC377195ns10:Originalns5:NetGoodwill2023-04-05SC377195ns10:Originalns5:NetGoodwill2022-04-05SC377195ns10:Originalns5:PlantMachinery2022-04-05SC377195ns10:Originalns5:PlantMachinery2023-04-05SC377195ns10:Originalns5:PlantMachinery2022-04-05SC377195ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-04-05SC377195ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-04-05SC377195ns10:Original1ns10:Director12022-04-05SC377195ns10:Original1ns10:Director12021-04-05SC377195ns10:Original1ns10:Director12022-04-062023-04-05SC377195ns10:Original1ns10:Director12021-04-062022-04-05SC377195ns10:Original1ns10:Director12023-04-05SC377195ns10:Original1ns10:Director12022-04-05
REGISTERED NUMBER: SC377195















ALHASSO ONCOLOGY LTD.

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 5 APRIL 2023






ALHASSO ONCOLOGY LTD. (REGISTERED NUMBER: SC377195)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023




Page

Balance Sheet 1

Notes to the Financial Statements 3


ALHASSO ONCOLOGY LTD. (REGISTERED NUMBER: SC377195)

BALANCE SHEET
5 APRIL 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 103,581 4,914
103,581 4,914

CURRENT ASSETS
Debtors 6 93,442 115,354
Cash at bank 477,748 363,883
571,190 479,237
CREDITORS
Amounts falling due within one year 7 43,167 43,272
NET CURRENT ASSETS 528,023 435,965
TOTAL ASSETS LESS CURRENT
LIABILITIES

631,604

440,879

CREDITORS
Amounts falling due after more than one
year

8

(43,523

)

-

PROVISIONS FOR LIABILITIES (25,895 ) (934 )
NET ASSETS 562,186 439,945

CAPITAL AND RESERVES
Called up share capital 102 102
Retained earnings 562,084 439,843
SHAREHOLDERS' FUNDS 562,186 439,945

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 5 April 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 5 April 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

ALHASSO ONCOLOGY LTD. (REGISTERED NUMBER: SC377195)

BALANCE SHEET - continued
5 APRIL 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 9 November 2023 and were signed by:





Dr A Alhasso - Director


ALHASSO ONCOLOGY LTD. (REGISTERED NUMBER: SC377195)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 5 APRIL 2023

1. STATUTORY INFORMATION

Alhasso Oncology Ltd. is a private company, limited by shares, registered in Scotland. The company's registered office is 41 Thorn Road, Bearsden, Glasgow, G61 4BP.

The financial statements are presented in Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

There were no material departures from this standard.

Judgements
The company considers on an annual basis the judgements that are made by management when applying its significant accounting policies that would have the most significant effect on amounts that are recognised in the financial statements. The director considers there are no such significant judgements.

Turnover
Turnover represents the invoice value of services rendered, excluding value added tax. The company's policy is to recognise income when the service has been provided to the patient.

Goodwill
Goodwill, being the difference between the amount paid for a business and the value of its separable net assets, is capitalised as an asset on the balance sheet. Goodwill was amortised over its estimated useful life of 10 years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Plant and machinery etc - 33.3% on cost, 25% on reducing balance and 15% on reducing balance

Tangible fixed assets are included at cost less accumulated depreciation and accumulated impairment losses.

Impairment of non-financial assets
At each reporting date non-financial assets not carried at fair value, like goodwill and plant and equipment, are reviewed to determine whether there is an indication that an asset may be impaired. If there is an indication of possible impairment, the recoverable amount which is the higher of value in use and the fair value less cost to sell, is estimated and compared with the carrying amount. If the recoverable amount is lower, the carrying amount of the asset is reduced to its recoverable amount and an impairment loss is recognised immediately in profit and loss.

ALHASSO ONCOLOGY LTD. (REGISTERED NUMBER: SC377195)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 5 APRIL 2023

2. ACCOUNTING POLICIES - continued

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable and loans with related parties.

Debt instruments like loans and other accounts receivable and payable are initially measured at present value of the future payments and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and trade creditors, are measured, initially and subsequently, at the undiscounted amount of cash or other consideration expected to be paid or received.

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for evidence of impairment and if found, an impairment loss is recognised in profit or loss.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Cash and cash equivalents includes cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts, when applicable, are shown within borrowings in current liabilities.

Taxation
Taxation represents the sum of tax currently payable and deferred tax. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

The charge for taxation takes into account taxation deferred as a result of timing differences between the treatment of certain items for taxation and accounting purposes. In general, deferred taxation is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. However, deferred tax assets are recognised only to the extent that the director considers that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted. Deferred taxation is measured on a non-discounted basis at the tax rates that are expected to apply in the periods in which the timing differences reverse, based on tax rates and laws enacted or substantively enacted at the balance sheet date.

With the exception of changes arising on the initial recognition of a business combination, the tax expense is presented either in profit or loss, other comprehensive income or statement of changes in equity depending on the transaction that resulted in the tax expense.

Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors.

Provisions
Provisions are recognised when the company has a legal or constructive obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle the obligation and the amount of the obligation can be reliably estimated. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

Hire purchase and lease commitments
Assets held under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to the profit and loss account over the relevant period. The capital element of the future payments is treated as a liability.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

ALHASSO ONCOLOGY LTD. (REGISTERED NUMBER: SC377195)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 5 APRIL 2023

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 6 April 2022
and 5 April 2023 140,000
AMORTISATION
At 6 April 2022
and 5 April 2023 140,000
NET BOOK VALUE
At 5 April 2023 -
At 5 April 2022 -

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 6 April 2022 13,535
Additions 114,796
At 5 April 2023 128,331
DEPRECIATION
At 6 April 2022 8,621
Charge for year 16,129
At 5 April 2023 24,750
NET BOOK VALUE
At 5 April 2023 103,581
At 5 April 2022 4,914

Tangible fixed assets include assets with net book value of £98,620 (2022: £nil) which are secured against hire purchase obligations.

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Other debtors 93,442 115,354

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Hire purchase contracts 10,237 -
Taxation and social security 20,995 31,858
Other creditors 11,935 11,414
43,167 43,272

ALHASSO ONCOLOGY LTD. (REGISTERED NUMBER: SC377195)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 5 APRIL 2023

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2023 2022
£    £   
Hire purchase contracts 43,523 -

9. SECURED DEBTS

The following secured debts are included within creditors:

2023 2022
£    £   
Hire purchase contracts 53,760 -

Hire purchase obligations are secured over the assets to which the agreements relate.

10. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 5 April 2023 and 5 April 2022:

2023 2022
£    £   
Dr A Alhasso
Balance outstanding at start of year 68,414 94,133
Amounts advanced 25,515 14,529
Amounts repaid (69,066 ) (40,248 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 24,863 68,414

During the year, interest of £923 (2022: £1,540) was charged on the loan account balance. Interest is charged at a commercial rate. The loan is unsecured and has no fixed repayment terms.